Testing for anti-human leukocyte antigen (HLA) antibodies has now become standard practice in allogeneic hematopoietic stem cell transplantation (HSCT), and anti-HLA antibodies (both donor specific and non-donor specific) are being identified and have many potential consequences. Most studies suggest that donor-specific HLA antibodies lead to adverse outcomes, though little is reported on non-donor specific anti-HLA antibodies. We present the results of a retrospective cohort analysis of 157 patients who received HSCT at the University of Rochester over a period of four years. We identified 45 patients (28.7%) who had detectable anti-HLA antibodies, while only one patient (0.6%) had donor-specific anti-HLA antibodies. Patients with prior pregnancies and multiple transfusions were at increased risk to develop antibodies. In our cohort, the presence of non-donor specific anti-HLA antibodies did not significantly impact overall survival, progression free survival, graft failure, or transplant-related mortality.

抗人白细胞抗原（HLA）抗体的测试现已成为同种异体造血干细胞移植（HSCT）的标准操作，并且抗HLA抗体（供体特异性和非供体特异性）已得到鉴定，并具有许多潜在的后果。大多数研究表明，供体特异性HLA抗体可导致不良后果，尽管非供体特异性抗HLA抗体报道很少。我们提供了对罗彻斯特大学四年期间接受HSCT的157例患者进行回顾性队列分析的结果。我们确定了45位患者（28.7％）的可检测抗HLA抗体，而只有一名患者（0.6％）的供体特异性抗HLA抗体。先前怀孕且多次输血的患者发生抗体的风险增加。在我们的队列中